Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

Perettie’s confidence stems from data shared at ASH on Dec. 6, when Kite revealed that patients treated with the Arcellx-partnered autologous therapy achieved a 96% overall response rate at the 15.9 ...

Biopharmaceutical company Gilead Sciences has hired Bob Allen as head of omnichannel strategy and digital transformation for public affairs.

After a yearslong court battle against a network of alleged HIV drug fraudsters, Gilead Sciences has emerged victorious with $175.2 million in judgments. Gilead has traveled a long road since the ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc., (Nasdaq: GILD) today announced $24 million in grants to help reduce health disparities, improve access to quality healthcare, advance ...